Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(33%)
Results Posted
100%(2 trials)

Phase Distribution

Ph not_applicable
2
67%
Ph early_phase_1
1
33%

Phase Distribution

1

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
N/ANon-phased studies
2(66.7%)

Highest Phase Reached

Early Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(2)

Detailed Status

Completed2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Early Phase 1

Trials by Phase

Early Phase 11 (33.3%)
N/A2 (66.7%)

Trials by Status

recruiting133%
completed267%

Recent Activity

1 active trials
Showing 3 of 3
completednot_applicable

Using Neuroeconomics to Characterize State-Based Increases and Decreases in Alcohol Value

NCT04067765
recruitingnot_applicable

tDCS and Urge in BFRBs

NCT07019571
completedearly_phase_1

Isradipine Enhancement of Virtual Reality Cue Exposure for Smoking Cessation

NCT03083353

Clinical Trials (3)

Showing 3 of 3 trials
NCT04067765Not Applicable

Using Neuroeconomics to Characterize State-Based Increases and Decreases in Alcohol Value

Completed
NCT07019571Not Applicable

tDCS and Urge in BFRBs

Recruiting
NCT03083353Early Phase 1

Isradipine Enhancement of Virtual Reality Cue Exposure for Smoking Cessation

Completed

All 3 trials loaded

Drug Details

Intervention Type
BEHAVIORAL
Total Trials
3